A Phase I-II Trial of Combined PKCι and mTOR Inhibition for Patients With Advanced or Recurrent Lung Cancer (NSCLC and SCLC) Without Standard Treatment Options
Phase of Trial: Phase I/II
Latest Information Update: 31 Aug 2017
At a glance
- Drugs Auranofin (Primary) ; Sirolimus (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 28 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.
- 25 Aug 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Jul 2017.
- 19 Apr 2016 Planned primary completion date changed from 1 Mar 2015 to 1 Mar 2017.